drugset / Trial / NCT05298696

Efficacy of Cilostazol in Prevention of Peripheral Neuropathy

NCT05298696

Phase 1/2 Completed 71 enrolled Mansoura University
RandomizedParallel-groupDouble-blindPrevention

Summary

There are several mechanisms concerning pathophysiology of paclitaxel induced peripheral neuropathy. One of the main mechanisms is induction of Schwann cell dedifferentiation by paclitaxel. At the preclinical level, cilostazol potently inhibited paclitaxel-induced dedifferentiation of cultured Schwann cells, yet this positive effect have not been clinically investigated.

Timeline

Start
2022-03-28
Primary completion
2022-10-30
Completion
2022-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cilostazol Small molecule 100 mg